Regulus Therapeutics Inc (NASDAQ:RGLS) has received a consensus recommendation of “Hold” from the nine ratings firms that are covering the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $6.00.

RGLS has been the topic of several analyst reports. Needham & Company LLC lowered shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, January 30th. Zacks Investment Research lowered shares of Regulus Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, March 8th. Wedbush reaffirmed an “outperform” rating and set a $6.00 price target on shares of Regulus Therapeutics in a research report on Wednesday, March 29th. Wells Fargo & Co lowered shares of Regulus Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, January 30th. Finally, Cantor Fitzgerald reduced their price target on shares of Regulus Therapeutics from $7.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, March 3rd.

Regulus Therapeutics (NASDAQ:RGLS) traded up 0.000% on Tuesday, hitting $1.375. The stock had a trading volume of 11,941 shares. Regulus Therapeutics has a 12 month low of $0.94 and a 12 month high of $6.25. The firm’s 50 day moving average price is $1.54 and its 200-day moving average price is $1.85. The stock’s market cap is $73.13 million.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Thursday, March 2nd. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.01. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.20 million. Regulus Therapeutics had a negative net margin of 573.63% and a negative return on equity of 70.38%. On average, analysts forecast that Regulus Therapeutics will post ($1.35) EPS for the current year.

In related news, Director William H. Rastetter bought 250,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 7th. The stock was purchased at an average price of $1.15 per share, for a total transaction of $287,500.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Stelios Papadopoulos bought 500,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 22nd. The stock was bought at an average price of $1.22 per share, with a total value of $610,000.00. Following the acquisition, the director now directly owns 400,677 shares in the company, valued at approximately $488,825.94. The disclosure for this purchase can be found here. 2.30% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of the stock. Tudor Investment Corp ET AL increased its stake in Regulus Therapeutics by 131.5% in the first quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 61,373 shares during the period. Geode Capital Management LLC increased its stake in Regulus Therapeutics by 3.4% in the first quarter. Geode Capital Management LLC now owns 265,774 shares of the biopharmaceutical company’s stock valued at $438,000 after buying an additional 8,729 shares during the period. Vanguard Group Inc. increased its stake in Regulus Therapeutics by 123.7% in the first quarter. Vanguard Group Inc. now owns 1,524,916 shares of the biopharmaceutical company’s stock valued at $2,516,000 after buying an additional 843,283 shares during the period. South Dakota Investment Council increased its stake in Regulus Therapeutics by 16.3% in the first quarter. South Dakota Investment Council now owns 1,327,058 shares of the biopharmaceutical company’s stock valued at $2,190,000 after buying an additional 186,130 shares during the period. Finally, Teachers Advisors LLC increased its stake in Regulus Therapeutics by 27.7% in the first quarter. Teachers Advisors LLC now owns 92,273 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 20,000 shares during the period. Hedge funds and other institutional investors own 50.10% of the company’s stock.

WARNING: This article was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/05/23/regulus-therapeutics-inc-rgls-receives-consensus-recommendation-of-hold-from-analysts.html.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

12 Month Chart for NASDAQ:RGLS

Receive News & Ratings for Regulus Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.